LYMPHOMAS

Mark Roschewski, MD, discusses the role Bruton’s tyrosine kinase inhibitor acalabrutinib has in aggressive B-cell lymphoma subgroups.

Richard Anderson, MD, PhD, discusses ways to preserve fertility in patients who are undergoing or have complete treatment for lymphoma.

Venetoclax in combination with EPOCH-R is safe and shows preliminary efficacy in patients with aggressive B-cell lymphoma.

Patrick Connor Johnson, MD, discusses what physicians take into consideration when considering third-line treatment options in diffuse large B-cell lymphoma.

Michael Wang, MD, professor in the Department of Lymphoma & Myeloma at the University of Texas MD Anderson Cancer Center, discusses the FDA approval of lisocabtagene maraleucel.

Subasumstat was found to have a manageable safety profile along with preliminary anti-tumor activity in patients with advanced or metastatic solid tumors or relapsed/refractory lymphoma.

Epcoritamab should be evaluated further after positive phase 1/2 results showing the agent was safe with preliminary antitumor activity.

The FDA is considering an application parsaclisib as treatment of patients with relapsed or refractory follicular lymphoma, marginal zone lymphoma, and mantle cell lymphoma, and granted priority review for 2 of the 3 indications.

Mazyar Shadman, MD, MPH, and Jonathon Cohen, MD, MS, discuss possible future developments with BTKi as therapy options in B-cell lymphomas.

Drs Shadman and Cohen introduce new data concerning a third-generation BTK inhibitor, pirtobrutinib, and discuss unmet needs in the B-cell malignancy landscape.

Mazyar Shadman, MD, MPH, and Jonathon Cohen, MD, MS, share their preferences regarding BTK-targeted treatment in B-cell malignancies.

Two experts discuss use of ibrutinib and zanubrutinib and data from the ALPINE and ELEVATE-RR trials.

A trial is currently recruiting across the US to investigate the safety of a new anti-PD-1/CD3 antibody for the treatment of relapsed or refractory T-cell lymphoma. It aims to enroll 86 patients.

Following treatment with chimeric antigen receptor T-cell therapy, patients with relapsed or refractory large B-cell lymphoma require more options. Investigators are now evaluating an interleukin-17 agent.

Many options exist for advanced stage cHL, with varying degrees of toxicity. Ranjana H. Advani, MD, gives an overview of each during a presentation at the NCCN 2021 Virtual Congress: Hematologic Malignancies.

Richard Anderson, PhD, discusses the effects lymphoma treatments have on fertility.

In an interview with Targeted Oncology, Richard Anderson, PhD discussed how fertility is impacted by many lymphoma treatments, and what can be done to help preserve fertility in patients prior to treatment.

Further research is warranted after a phase 1 study found the agent has a good safety profile with clinical efficacy.

Mazyar Shadman, MD, MPH, and Brian T. Hill, MD, PhD, consider potential treatment options for relapsed/refractory diffuse large B-cell lymphoma in the future.

Two experts examine bispecific antibody treatment use for relapsed/refractory diffuse large B-cell lymphoma.

Drs Shadman and Cohen discuss clinical trial data utilizing acalabrutinib in B-cell lymphomas.

Two experts compare experiences and data concerning use of ibrutinib, acalabrutinib, and zanubrutinib in B-cell lymphomas.

In an interview with Targeted Oncology, Patrick Connor Johnson, MD, discussed the top considerations taken into account by physicians when choosing a third-line therapy for diffuse large B-cell lymphoma.

Axi-cel developer seeks to expand Axi-Cel for large B-cell lymphoma application to include the second-line setting.

Drs Shadman and Cohen provide an overview of clinical trials utilizing the BTK inhibitor, ibrutinib, for B-cell lymphomas.